Arbutus Biopharma Corporation
IPOHome - Arbutus Biopharma
Public · Burnaby, Canada · Founded 2015 · $116.0M raised
- Headquarters
- Burnaby
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- arbutusbio.com
- Total Funding
- $116.0M
- Last Round
- $116.0M Corporate RoundOct 2017
- Rounds
- 1
- Type
- Public
About
Arbutus Biopharma (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (HBV) infection. Its pipeline includes RNAi therapeutics, immune modulators, and antivirals designed to be used in combination to suppress the virus and restore immune control in patients.
Summary
Arbutus Biopharma Corporation is a Biotech company based in Burnaby, Canada, founded in 2015. It has raised $116.0M in total across 1 round, most recently a $116.0M Corporate Round round in Oct 2017. Investors include Roivant Sciences.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2017
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...